Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients

Completed

• Conditions: Rheumatoid Arthritis; Covid19

• Registration Number: NCT04679272
• Lead Sponsor: University Hospital, Montpellier

Brief Summary

COVID-19 is an infectious disease caused by SARS-CoV2 virus. The objective of our study is to analyze the progression and the severity of COVID-19 in patients with RA. Indeed, few data are available on this subject, and this would allow us to improve management of COVID-19 in these potential at-risk patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-12-01
• Study First Submitted: 2020-12-20
• Study First Submitted QC: 2020-12-20
• Study First Posted: 2020-12-22
• Primary Completion: 2021-01-30
• Status Verified: 2021-02
• Study Completion: 2021-02-01
• Last Update Submitted: 2021-02-26
• Last Update Posted: 2021-03-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hospitalization rates for COVID-19	1 day	Proportion of hospitalized patients in RA group or control group. From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

Secondary Outcome Measures

Name	Time	Method
Age	1 day	Patients demographics From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Number of Participants with co-morbidities	1 day	Patients comorbidities From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Type of clinical presentation	1 day	Patients COVID-19 clinical presentation From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Critical care transfer rate for COVID-19 and death due to COVID-19	1 day	Proportion of patients transferred in critical care for COVID-19 or deaths due to COVID-19 From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Pulmonary comorbidities, corticosteroids or DMARDs use	1 day	Type and severity of patients pulmonary comorbidities and treatment by corticosteroids or DMARDs in RA group From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Type of associated treatments	1 day	From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

Trial Locations

Locations (1)

UH Montpellier; 🇫🇷 Montpellier, France